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Parasitic helminths infect over 1 billion people worldwide, while current treatments rely on a limited 
arsenal of drugs. To expedite drug discovery, we screened a small-molecule library of compounds 
with histories of use in human clinical trials for anthelmintic activity against the soil nematode 
Caenorhabditis elegans. From this screen, we found that the neuromodulatory drugs sertraline, 
paroxetine, and chlorpromazine kill C. elegans at multiple life stages including embryos, developing 
larvae and gravid adults. These drugs act rapidly to inhibit C. elegans feeding within minutes of 
exposure. Sertraline, paroxetine, and chlorpromazine also decrease motility of adult Trichuris 
muris whipworms, prevent hatching and development of Ancylostoma caninum hookworms and kill 
Schistosoma mansoni flatworms, three widely divergent parasitic helminth species. C. elegans mutants 
with resistance to known anthelmintic drugs such as ivermectin are equally or more susceptible to these 
three drugs, suggesting that they may act on novel targets to kill worms. Sertraline, paroxetine, and 
chlorpromazine have long histories of use clinically as antidepressant or antipsychotic medicines. They 
may represent new classes of anthelmintic drug that could be used in combination with existing front-
line drugs to boost effectiveness of anti-parasite treatment as well as offset the development of parasite 
drug resistance.
More than 1 billion people world-wide are estimated to be infected with parasitic helminths, resulting in major 
economic and personal impacts from the years of healthy life lost to morbidity and premature mortality1,2. Effects 
of chronic helminth infection particularly impact pregnant mothers and children, resulting in worsened birth 
outcomes, anemia, developmental delays, stunting, and educational challenges. Chemotherapeutic control of hel-
minth infections has relied exclusively on the use of a single drug or related classes of drugs over extended periods 
of time, a strategy that supports selection of anthelmintic-resistant parasites. In fact, resistance to the existing 
front-line drugs has been detected in livestock and companion animals, and is likely to occur in human helminths 
as well3,4. The identification of new pharmaceutical agents that can cheaply and effectively treat parasitic helminth 
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infections is a critical global health need. However, the journey from initial development to approval for use in 
humans is long and costly, and it is estimated to exceed 2.5 billion dollars to bring a single new drug to market5. 
Many consumers of anthelmintic drugs are in poor countries with inadequate infrastructure and public health 
budgets, requiring a low price point per dose to put medication within reach. This means there is likely to be a 
lower return on investment for the cost of developing a new drug despite the large number of people that would 
utilize and benefit from it. Repurposing existing clinically approved drugs for anthelmintic use could significantly 
decrease the cost to develop and translate a new drug to the clinic.
High-throughput compound screening in parasitic helminths is impractical due to the associated costs as 
well as the difficulties of culturing and maintaining populations of parasites with multiple life-stages requir-
ing different growth environments, including time within a mammalian host. Therefore, developing low-cost, 
high-throughput screening platforms to identify lead compounds is critical. Identifying compounds that kill 
Caenorhabditis elegans, a non-parasitic soil dwelling nematode, can help direct researchers toward drugs that also 
kill parasitic helminths. Front-line anthelmintic drugs can kill C. elegans, and C. elegans have been used to iden-
tify novel lead compounds for additional study as well as to dissect the target pathways of known anthelmintic 
drugs6,7. C. elegans are amenable to low- and high-throughput screens, have a rapid life cycle, and are easy to 
maintain in a laboratory setting. Therefore, C. elegans provides a cost-effective and rapid screening tool to identify 
new anthelmintic candidates, which can then be followed by testing on targeted parasitic species.
Adopting this strategy, we used C. elegans for first-pass screening of the NIH Clinical Collection, a library of 
small molecules with histories of use in humans. These compounds have associated data pertaining to safety, bio-
availability, and dosage, which will expedite repurposing for new indications. From these screens, we identified 
three drugs that effectively kill C. elegans at multiple life stages. Furthermore, these drugs are toxic to three para-
sitic helminth species: the whipworm, Trichuris muris; the hookworm, Ancylostoma caninum; and the blood fluke 
flatworm, Schistosoma mansoni. Analysis of C. elegans strains with mutations in specific biochemical pathways 
suggest that the drugs may act via novel pathways, potentially representing new classes of anthelmintics that can 
be rapidly translated into the clinic.
Results
Sertraline, paroxetine, and chlorpromazine are toxic to multiple C. elegans developmental 
stages. To identify novel anthelmintic drug candidates, we surveyed 281 compounds from the NIH Clinical 
Collection for activities that inhibited C. elegans hatching, development, growth, and/or survival. From this 
screen, we identified 13 FDA-approved drugs that reproducibly caused rapid death or early developmental 
arrest of C. elegans (Supplementary Table S1). These drugs have diverse clinical indications, including uses as 
anti-arrhythmia, anti-bacterial, anti-cancer, anti-depressant, anti-fungal, and anti-psychotic agents. We selected 
sertraline, paroxetine, and chlorpromazine for follow-up testing based on their reported tolerability, oral bioavail-
ability, low toxicity, and limited side effect profiles in humans.
Parasitic helminths are typically present in several developmental stages in an infected human, and efficacy 
against more than one parasite life stage can reduce the number of treatments required or prevent the need to use 
a combination drug therapy targeting different life stages. Accordingly, we tested the drugs at a range of concen-
trations in multiple C. elegans life stages: embryos, larvae, and fully developed, fertile adults. Worms were placed 
on solid agar plates with the indicated concentrations of drug (Table 1) and scored using a partially quantitative 
severity scoring system for effects on motility, development, and survival. Worm populations were assigned a 
phenotypic description after 48 h of drug exposure. Each negative phenotype observed was assigned a point and 
these were summed to obtain a total severity score for each drug and concentration tested, similar to a recently 
reported health-rating system developed for C. elegans anthelmintic screening8. We found that sertraline, par-
oxetine, and chlorpromazine all had concentration-dependent, deleterious effects on development, motility and 
survival at all life stages tested (Table 1).
Additional quantitative data were obtained by scoring the percentage of live worms 48 h after exposing 
embryos to drugs. All three drugs had concentration-dependent effects on survival (Fig. 1A–D). Comparison 
of IC50 values (the concentration of drug that caused 50% lethality) showed that the order of potency was ser-
traline > paroxetine > chlorpromazine. We also observed strong developmental delay or arrest at 48 h after expo-
sure to the drugs (Supplementary Table S2). To quantify drug effects on C. elegans motility, we utilized automated 
video worm tracking software. Day 1 adult worms were placed on plates containing the indicated concentrations 
of drug for 24 h, at which point unstimulated locomotion was recorded and analyzed. All three drugs caused 
concentration-dependent decreases in motility, with similar potency (Fig. 1E–H).
Sertraline, paroxetine, and chlorpromazine act through non-canonical targets to kill C. elegans. 
Sertraline and paroxetine are selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs), 
used clinically as anti-depressant medications. These drugs are known to inhibit the 5-HT reuptake transporter 
SCL6A4, resulting in an increase in the amount of extracellular 5-HT and increased 5-HT receptor activation9. 
Sertraline has been shown to reduce schistosomulum viability in the trematode parasite, S. mansoni10. In C. 
elegans, S. mansoni, Ascaris suum (pig roundworm), and some plant nematodes, treatment with 5-HT can cause 
altered movement or paralysis11–14, whereas in many free living and parasitic nematodes 5-HT stimulates feeding 
behavior15–17.
Drugs that perturb serotonergic signaling thus have potential as anthelmintics, but it is important to iden-
tify the molecular targets upon which the drugs act. To test the role of specific genes in the anthelmintic activ-
ity of these drugs, mutant and wild-type C. elegans embryos were placed on solid agar plates with a range of 
drug concentrations effective on wild-type C. elegans, and scored semi-quantitatively for positive or negative 
effects on population development, motility and survival compared to wild-type worms. The toxicity of sertraline 
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and paroxetine could potentially result from their canonical SSRI activities, acting on the C. elegans functional 
homolog of SCL6A4, MOD-518, and increasing bioavailable 5-HT. To test this hypothesis, we determined whether 
a mod-5 loss of function mutant was resistant to the effects of sertraline and paroxetine. Interestingly, we found 
that mod-5(n822) mutant worms were more sensitive to sertraline and paroxetine than wild-type controls 
(Supplementary Table S3), suggesting that these drugs acted via another target or targets in C. elegans. We also 
tested whether the C. elegans gene with the next highest sequence homology to SCL6A4, the dopamine (DA) 
transporter dat-1, was important for mediating drug susceptibility. We found that the dat-1 loss-of-function 
mutation dat-1(ok157) was not more resistant to sertraline or paroxetine than wild-type controls (Supplementary 
Table S3). In addition, we tested loss of function mutations in tph-1(n4622), tryptophan hydroxylase required 
for 5-HT biosynthesis; four identified serotonin-binding receptors in C. elegans: mod-1(ok103), ser-4(ok512), 
ser-7(tm1325) and ser-1(ok345); and glr-1(n2641), an AMPA receptor that functions downstream of ser-7. None 
of these mutants exhibited differences in susceptibility to sertraline or paroxetine compared to wild-type worms, 
despite their key roles in 5-HT synthesis or signaling (Supplementary Table S3).
A number of C. elegans mutants have been generated previously with resistance to a nose-retraction pheno-
type in the presence of low doses of fluoxetine (Prozac), another SSRI antidepressant19. Two of these mutants were 
mapped to specific genetic loci and characterized for their roles in C. elegans19,20. One of them, nrf-5, encodes 
a lipid-binding protein involved in hydrophobic molecule transport in the intestine, while the other, nrf-6, is 
involved in embryonic viability and yolk transport. We tested whether these fluoxetine-resistant mutants were 
also resistant to sertraline and paroxetine. The survival of nrf-5(sa513) worms in these drugs was unchanged from 
wild-type C. elegans. Interestingly, nrf-6(sa525) worms were more sensitive than wild-type to paroxetine, although 
not to sertraline (Supplementary Table S3). The finding that mutations in the genes listed in Supplementary 
Table S3 failed to reduce the anthelmintic activity of sertraline and paroxetine in C. elegans worms suggested that 
one or more other targets of these drugs underlie their anthelmintic effects.
Chlorpromazine gained widespread use in the 1950’s as the first neuroleptic drug, and is thought to primarily 
act through antagonism of DA D2 receptors21. Chlorpromazine has been reported to decrease embryonic survival 
in C. elegans and Haemonchus contortus (a parasitic nematode of ruminants)22, kill L3 larvae of Ancylostoma cey-
lanicum (hookworm)23, and reduce the motility of Dirofilaria immitis (canine heartworm)24. Exogenously applied 
DA can also reduce movements of Meloidogyne incognita and Heterodera glycines, two parasitic nematodes of 
plants11. As with SSRI drugs, the molecular target or targets that underlie the anthelmintic activity of chlorprom-
azine have not been identified.
To test the hypothesis that D2 receptor antagonism is required for the anthelmintic activity of chlorpromazine, 
we tested its effects on C. elegans with loss of function mutations in both D2-like receptors, DOP-2 and DOP-3. 
We found that the dop-2(vs105); dop-3(vs106) mutant worms were not more resistant to chlorpromazine than 
wild-type C. elegans (Supplementary Table S3). We also tested loss of function mutations in cat-2(e1112), tyrosine 
hydroxylase required for DA synthesis, and dat-1(ok157), the C. elegans DA transporter. cat-2(e1112) worms were 
more sensitive to chlorpromazine, while dat-1(ok157) and wild-type worms had similar sensitivity to chlorprom-
azine. These findings suggested that intact DA signaling was not required for this drug’s anthelmintic activity.
Chlorpromazine has a number of other known targets, including 5-HT, histamine, α-adrenergic, and mus-
carinic receptors25. To begin exploring these candidate pathways, we tested the sensitivities of the 5-HT sig-
naling mutants tph-1(n4622), mod-1(ok103), mod-5(n822), ser-4(ok512), and ser-7(tm1325); ser-1(ok345) to 
Embryos DMSO 5 μM 25 μM 50 μM 75 μM 100 μM 125 μM 150 μM
Sertraline 0 0 1 4 4 4 4 4
Paroxetine 0 0 1 3 4 4 4 4
Chlorpromazine 0 0 0 1 3 4 4 4
L1 DMSO 5 μM 25 μM 50 μM 75 μM 100 μM 125 μM 150 μM
Sertraline 0 0 1 4 4 4 4 4
Paroxetine 0 0 1 1 4 4 4 4
Chlorpromazine 0 0 0 0 2 2 4 4
L3/L4 DMSO 5 μM 25 μM 50 μM 75 μM 100 μM 125 μM 150 μM
Sertraline 0 0 0 2 2 3 4 4
Paroxetine 0 0 0 0 1 2 4 4
Chlorpromazine 0 0 0 0 0 1 1 4
Adults DMSO 5 μM 25 μM 50 μM 75 μM 100 μM 125 μM 150 μM
Sertraline 0 0 1 3 4 4 4 4
Paroxetine 0 0 0 1 4 4 4 4
Chlorpromazine 0 0 0 0 4 4 4 4
Table 1. Drug effect severity scores for C. elegans. C. elegans were grown in the presence of the indicated 
concentrations of drug and scored for visible phenotypes. All treatments were performed in duplicate wells, 
N = 50–100 worms/well, with each experiment repeated at least 3 times. Points were assigned for each scored 
effect based on the scoring descriptors below after 48 h of drug exposure and additive for each phenotype 
observed, with a maximum allowed total score of 4. Scoring descriptors were assigned when the entire test 
population exhibited the phenotype. Arrested = 1; Developmental delay = 1; Lethargic = 1; Paralyzed = 1; Toxic 
(>90% lethality) = 2; Dead = 4.
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Figure 1. Sertraline, paroxetine, and chlorpromazine impair survival and motility in C. elegans. (A,B,C) 
Embryos were placed on plates containing the indicated concentrations of drug, and hatched embryos were 
scored at 48 h for survival (mean ± S.E.M.; N = 6 replicates; 50–100 embryos plated per replicate). In every 
case, there was a significant effect of the drug on survival (p < 10−10; Likelihood Ratio test). (E,F,G) Day 1 adult 
worms were exposed to sertraline, paroxetine, or chlorpromazine on plates for 24 h. Worm movements were 
video recorded and movement speeds calculated using automated tracking analysis software (WormLab). Data 
are shown as mean ± S.E.M.; N = 3 replicates; > 40 individual worms tracked per concentration. In every case, 
there was a significant effect of the drug on motility (p < 10−10; Likelihood Ratio test). Smooth curves in (A–H) 
are best fits to the Hill equation (see Materials and Methods). (D) and (H) show the superimposition of the 
curves in (A–C) and (E–G), respectively, for comparison. Calculated IC50 values (the drug concentration at 
which survival or motility were reduced by 50%) are shown. Pairwise comparisons of IC50 values for lethality 
showed significant differences between all 3 three drugs (p < 10−8; Likelihood Ratio test; D), but there were no 
significant differences in IC50 for the motility assay between drugs (p > 0.08; H).
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Figure 2. Sertraline, paroxetine and chlorpromazine inhibit pharyngeal pumping in C. elegans. Pumping 
in day 1 adults was monitored by EPG recordings obtained in a microfluidic chip, in M9 buffer containing 
10 mM 5HT (M9-5HT). After 30 min perfusion with M9-5HT the perfusate was switched (grey bars) to 
M9-5HT containing drug or solvent. Only a portion of the baseline recording period is shown. (A) Excerpts 
of representative EPG recordings from 4 individual worms switched to (top to bottom): 200 µM sertraline 
(SRT); 500 µM paroxetine (PXT); 1000 µM chlorpromazine (CPZ); and 0.5% DMSO (CON). In these time-
compressed recordings, individual pumps are not visible and pumping appears as a thick, dark line. Insets 
at an expanded time base (top) show the characteristic decrease in pump frequency and EPG amplitude 
caused by all 3 drugs. (B,C,D) Concentration- and time-dependence of pump inhibition by SRT, PXT and 
CPZ, compared to controls. Pump frequency was normalized to the frequency prior to switching perfusate 
and displayed as mean (line) ± S.E.M. (shading). (E,F,G) Pump frequency from (B,C,D) was plotted against 
drug concentration at t = 55–60 min (mean ± S.E.M.) and fit using the Hill equation. Number of worms per 
point (N) shown in parentheses. In every case, there was a significant effect of the drug on pump frequency 
(p < 10−10; Likelihood Ratio test). (H) Superimposition of the curves in (E,F,G) for comparison. Calculated 
IC50 values (the drug concentration at which pump frequency was reduced by 50%) are shown. The IC50 value 
for sertraline differed significantly from the values for paroxetine (p < 10−7) and chlorpromazine (p < 10−4) 
whereas chlorpromazine and paroxetine IC50s did not differ significantly (p > 0.2; Likelihood Ratio test).
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chlorpromazine, but none exhibited any increased resistance to chlorpromazine (Supplementary Table S3). In 
summary, the finding that mutations in the genes listed in Supplementary Table S3 failed to reduce the ability of 
chlorpromazine to kill C. elegans worms suggests that one or more other targets of this drug underlies its anthel-
mintic effects.
Potentially, the anthelmintic activity of sertraline, paroxetine and chlorpromazine on C. elegans might be 
mediated through other neurotransmitter signaling pathways. Therefore, we tested whether genetic disruption of 
octopamine (OA) or tyramine (TYR) signaling would alter worms’ susceptibilities to these drugs. We tested the 
TYR receptor ser-2(pk1357); two alleles of the OA receptor ser-3 (ok2007 and ad1774); the TYR decarboxylase 
required for synthesis of TYR and OA, tdc-1(n3419); and the TYR beta-hydroxylase required for TYR synthesis, 
tbh-1(n3247). However, none of these mutants were less sensitive than controls to sertraline, paroxetine, or chlor-
promazine (Supplementary Table S3).
C. elegans have been used to dissect anthelmintic drug mechanisms of action, primarily through the selection 
of drug-resistant mutants, leading to identification of key target pathways. We expected that, if sertraline, parox-
etine or chlorpromazine acted on the same targets as known anthelmintic drugs, mutants resistant to the known 
Figure 3. Sertraline, paroxetine and chlorpromazine inhibit motility of adult T. muris. (A,B,C) Adult worms 
were cultured in different concentrations of sertraline, paroxetine or chlorpromazine for 24 h, after which 
their movements were videotaped and analyzed. Motility was normalized to the motility of medium-only, and 
medium with 1% DMSO, controls at 24 h. Data are shown as mean ± S.E.M.; N = 3 replicates; 3 worms per 
replicate. In every case, there was a significant effect of the drug on motility (p < 10−10; Likelihood Ratio test). 
(D) Superimposition of the curves in (A,B,C) for comparison. Calculated IC50 values (the drug concentration 
at which motility was reduced by 50%) at 24 h are shown. At 24 h, the IC50 value for chlorpromazine differed 
significantly from the values for sertraline (p < 10−10) and paroxetine (p < 10−5) whereas sertraline and 
paroxetine IC50s barely differed (p = 0.48; Likelihood Ratio test). (E) IC50 values for T. muris motility computed 
at four earlier time points (1, 4, and 12 h) in addition to the 24-h data in (A–D). The same worms were analyzed 
at each time point and IC50s were calculated from Hill plots (not shown). At 1 h post-treatment, the IC50 of 
sertraline differed significantly from the values for paroxetine (p = 0.006) and chlorpromazine (p = 0.04), 
whereas the IC50s of paroxetine and chlorpromazine did not differ significantly (p = 0.26; Likelihood Ratio test).
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anthelmintics should likewise exhibit resistance to sertraline, paroxetine and/or chlorpromazine. Therefore, we 
tested mutants resistant to emodepside (slo-1(js379)), Bacillus thuringiensis (BT) toxin (bre-1(ve4)), levamisole 
(unc-29(e193) and unc-50(e306)), monepantel (acr-23(ok2804)), ivermectin (avr-14(ad1305);avr-15(vu227);glc-
1(pk54)), or benzimidazole (ben-1(e1880))26–31 representing a broad range of anthelmintic targets and modes of 
Figure 4. Sertraline, paroxetine and chlorpromazine impair hatching and development of A. caninum. 
Hookworm eggs were placed on plates containing the indicated concentrations of drug and scored for hatching 
and development after 4 d. The results of two pooled experiments (N = 6 replicates, 100 eggs per replicate) for 
each drug at each concentration are represented two ways. (A,B,C) Percentage of eggs that hatched. (E,F,G) 
Percentage of hatched worms that developed beyond the L1 stage. Panels D and H show the plots in (A–C and 
E–G), respectively, superimposed for comparison. Calculated IC50 values (the drug concentration at which 
hatching or development were reduced by 50%) are shown. The IC50 for percent hatched in sertraline differed 
significantly from the IC50s for chlorpromazine (p < 10−6) and paroxetine (p < 0.002; D). The IC50 for percent 
developing per hatched in sertraline differed significantly from paroxetine (p < 0.002; H). All other IC50 
comparisons were not significantly different (p > 0.4; Likelihood Ratio test).
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action. However, none of the resistance mutants tested were more resistant to sertraline, paroxetine or chlorprom-
azine than wild-type worms (Supplementary Table S3), suggesting that the anthelmintic activities of these drugs 
on C. elegans may be mediated via previously unidentified targets or pathways.
Sertraline, paroxetine, and chlorpromazine rapidly inhibit C. elegans pharyngeal pumping. 
Many existing anthelmintics act via ion channels or neurotransmitter receptors32. Sertraline, paroxetine and 
chlorpromazine are all candidates for this mode of action, even if their specific targets are as yet unknown. To 
test whether these drugs exerted rapid effects on electrical signaling, we used a microfluidic device (‘chip’) to 
record electropharyngeograms (EPGs) from C. elegans adults while perfusing control or drug solutions over 
the worms16,33. This non-invasive method records the electrical currents emitted by pharyngeal muscles and 
neurons during pharyngeal pumping (feeding behavior). 5-HT was included in the perfused solutions to induce 
robust, sustained pharyngeal pumping, providing a baseline against which feeding-inhibitory effects could be 
quantified. Known anthelmintic drugs that act on ion channels or neurotransmitter receptors rapidly inhibit 
EPG activity16,33.
Continuous EPG recordings were taken while switching from the control solution to a drug or control 
solution (Fig. 2). Drug concentrations were selected to span a range of effectiveness suitable for determining 
IC50 values (the concentration at which pumping frequency was reduced by half ). We found that all three 
drugs reduced the frequency of pharyngeal pumping, or terminated it completely, while control worms contin-
ued to pump at the control rate (Fig. 2A). The drugs also diminished the amplitude of EPG signals compared 
to controls (insets, Fig. 2A). Inhibition of pharyngeal pumping by sertraline, paroxetine and chlorpromazine 
was rapid—sometimes within 5 min—and concentration-dependent (Fig. 2B,C,D). The rapidity of the inhi-
bition was consistent with perturbation of ion channels or neurotransmitter receptors. Dose-response curves 
(Fig. 2E,F,G,H) and statistical comparison of IC50 values showed that sertraline was the most potent, with par-
oxetine and chlorpromazine having similar potencies. Taken together, these results suggest that disruption of 
electrical signaling, and potentially the disruption of feeding behavior, could contribute to the lethality of ser-
traline, paroxetine and chlorpromazine. In these experiments, all three drugs inhibited pharyngeal pumping in 
the presence of a relatively high level of 5-HT (10 mM); this finding is consistent with the results of the mutant 
analysis above (Supplementary Table S3) which likewise suggested that the drugs’ deleterious effects were not 
mediated by an increase in 5-HT levels.
Sertraline, paroxetine, and chlorpromazine decrease motility of the parasitic whipworm 
Trichuris muris. Although many studies have utilized C. elegans as a surrogate screening platform for anthel-
mintic compounds, it is not clear which parasitic species are best modeled by C. elegans nor whether a novel 
intervention that kills C. elegans will be effective in other species. Therefore, we tested the effects of sertraline, 
paroxetine and chlorpromazine against Trichuris muris, a whipworm parasite of mice similar to the human par-
asite Trichuris trichiura. T. muris adults were isolated from infected mice, maintained in vitro in culture dishes, 
exposed to drugs, and monitored every 4 h for 24 h. Parasite movements were captured by video and analyzed 
for changes in motility over time. All three drugs produced concentration-dependent reductions in motility, 
as shown in Fig. 3A,B,C,D for the 24 h time point. Statistical comparison of IC50 values showed that, at 24 h, 
chlorpromazine was the most potent in reducing motility compared to sertraline and paroxetine. Figure 3E 
presents IC50 data for additional times post-treatment. As expected, IC50 values decreased as exposure time 
increased. For the first 8 h of exposure, the order of potency was sertraline > chlorpromazine > paroxetine. At 
12 h post-treatment, the IC50s were similar. Finally, at 24 h, chlorpromazine was significantly more effective than 
either other drug in impairing motility.
Somules
18 hours 48 hours
DMSO 0.625 μM 1.25 μM 2.5 μM 5 μM 10 μM DMSO 0.625 μM 1.25 μM 2.5 μM 5 μM 10 μM
Sertraline 0 0 0 1 4 4 0 0 0 1 4 4
Paroxetine 0 2 2 2 4 4 0 2 2 4 4 4
Chlorpromazine 0 2 2 2 2 4 0 2 2 2 2 4
Adult Males
11 hours 24 hours
DMSO 0.625 μM 1.25 μM 2.5 μM 5 μM 10 μM DMSO 0.625 μM 1.25 μM 2.5 μM 5 μM 10 μM
Sertraline 0 0 0 0 0 4 0 0 0 0 2 4
Paroxetine 0 1 1 1 1 4 0 1 1 1 1 4
Chlorpromazine 0 0 1 1 1 2 0 0 1 1 1 3
Table 2. Drug effect severity scores for S. mansoni. S. mansoni somules or adult males were incubated for the 
indicated durations and concentrations of drug, and scored for phenotypic changes. Assays were performed 
in duplicate wells with either 40 somules or 5 adult male worms per well. Data from one of two experiments 
are shown. Each phenotypic descriptor observed was awarded a score of 1 and the scores were added up to a 
maximum score of 4, as indicated below. The most severe descriptors received a score of 4. Descriptors and 
their scores were assigned when the entire test population exhibited the phenotype. Dark = 1; Male suction 
impaired = 1; Overactive = 1; Rounded = 1; Slow = 1; Uncoordinated = 1; Degenerating = 4; Tegument damage 
(adults) = 4; Dead = 4.
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Sertraline, paroxetine, and chlorpromazine are toxic to the hookworm Ancylostoma caninum. 
We next tested the effects of sertraline, paroxetine and chlorpromazine on the hookworm, Ancylostoma caninum. 
A. caninum, a significant pathogen of dogs and a commonly-used laboratory surrogate for human hookworms, 
is highly diverged from T. muris. A. caninum embryos were isolated from infected dogs and cultured in the pres-
ence of a range of concentrations of sertraline, paroxetine or chlorpromazine. After 24 h the worms were scored 
for hatching and development in the presence of drug (Fig. 4). We found that A. caninum embryos exposed to 
sertraline, paroxetine or chlorpromazine exhibited concentration-dependent failure to hatch (Fig. 4A,B,C), with 
sertraline being more potent than paroxetine or chlorpromazine (Fig. 4D). In embryos that were able to hatch, all 
three drugs caused concentration-dependent inhibition of development beyond the L1 stage (Fig. 4E,F,G). The 
three drugs had generally similar potencies, with sertraline being the most potent in this assay (Fig. 4H) as well as 
in the hatching assay (Fig. 4D). In summary, all three drugs significantly inhibited the hatching and development 
of A. caninum eggs.
Figure 5. Phenotypic changes in S. mansoni somules (post-infective larvae) following incubation with 
sertraline, paroxetine or chlorpromazine. Images were obtained after 48 h in culture with either DMSO (control) 
or the indicated concentrations of drugs. (A) Control somules. (B) 5 µM sertraline produced rounding, 
degeneration and death. (C) 5 µM paroxetine produced rounding and degeneration. (D) 5 µM chlorpromazine 
produced somule lengthening and overactivity, whereas (E) 10 µM chlorpromazine produced rounding and 
degeneration. Scale bar = 200 µm. Additional phenotypic data are given in Table 2.
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Sertraline, paroxetine, and chlorpromazine kill the parasitic flatworm Schistosoma mansoni. 
To examine the effects of sertraline, paroxetine and chlorpromazine on a third parasitic helminth species, we 
tested them on the blood fluke, Schistosoma mansoni. This schistosome species is prevalent in Africa and South 
America, and is highly divergent from the nematodes, C. elegans, T. muris and A. caninum. S. mansoni somules 
(post-infective larvae in the mammalian host) were isolated, exposed to sertraline, paroxetine or chlorprom-
azine and surveyed at 18 and 48 h post-treatment for morphological changes and survival. Using a partially 
quantitative severity scoring system based on the phenotypes observed, including changes in opacity and shape, 
impaired motility, impaired sucker adherence, degeneration and death, all three drugs caused dramatic, time- and 
concentration-dependent morphological changes in somules (Table 2; Fig. 5). Sertraline and paroxetine produced 
the most severe effects.
We also tested the three drugs on adult S. mansoni; degenerative changes were scored at 11 and 24 h (Table 2) 
and worm motility was measured at 1, 5, 11 and 24 h over five concentrations of drug (Fig. 6). Adults exhibited a 
range of phenotypes including uncoordinated movements and impaired adherence to the bottom of the culture 
well via the ventral sucker, with sertraline and paroxetine producing the most severe effects (Table 2). For motil-
ity testing of adult S. mansoni, the temporal response pattern varied by drug and concentration (Fig. 6A,B,C). 
Paroxetine and chlorpromazine produced an early phase of hyperactivity that returned toward control levels 
over time. At 24 h post-treatment, sertraline and paroxetine both caused a concentration-dependent impairment 
of motility (Fig. 6D,E), whereas chlorpromazine did not (Fig. 6F), even though chlorpromazine caused adverse 
Figure 6. Effects of sertraline, paroxetine and chlorpromazine on motility of adult S. mansoni. Adult male 
worms were cultured in the presence of sertraline, paroxetine, chlorpromazine or DMSO at the indicated 
concentrations. Motility was measured using WormAssay after 1, 5, 11 and 24 h (N = 4 replicates, 60 s recording 
period) and normalized to DMSO controls (set to 100%). (A,B,C) Motility (mean ± S.E.M.) plotted against time 
for the drug concentrations shown. (D,E,F) Motility plotted against concentration at 24 h (same data as A,B,C). 
The sertraline and paroxetine data could be fitted by the Hill equation whereas the chlorpromazine data could 
not (a linear fit is shown). Both sertraline and paroxetine had significant effects on motility at 24 h (p < 10−10; 
Likelihood Ratio test). (G) Shows the plots from (D) and (E) superimposed for comparison. Calculated IC50 
values (the drug concentration at which motility was reduced by 50%) are shown. IC50 values for sertraline and 
paroxetine were not significantly different (p = 0.66; Likelihood Ratio test).
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phenotypic changes (Table 2). In summary, S. mansoni somules and adults were most sensitive to sertraline and 
paroxetine, with chlorpromazine causing less severe effects.
Taken together, the experiments above suggest that anthelmintic activity of sertraline, paroxetine, and chlor-
promazine may be conserved across more than 1 billion years of evolution, following the separation of nematodes 
such as C. elegans, T. muris and A. caninum from trematodes like S. mansoni34.
Discussion
In this study, we found that thirteen FDA-approved drugs in the NIH Clinical Collection library exhibit anthel-
mintic activity in C. elegans. Based on their favorable pharmacological and safety profiles in humans, we selected 
sertraline, paroxetine (two SSRI inhibitor anti-depressant drugs) and chlorpromazine (a DA D2 receptor antago-
nist anti-psychotic drug) for further characterization in C. elegans and three parasitic helminths. In C. elegans, the 
drugs impaired development and motility, killed multiple life stages and rapidly disrupted pharyngeal pumping. 
In T. muris, the drugs impaired motility of adult worms. In A. caninum, the drugs impaired hatching and devel-
opment. Finally, in S. mansoni, the drugs caused degeneration and death of somules, and impaired motility and 
death of adult worms. Thus, sertraline, paroxetine and chlorpromazine all exhibit significant anthelmintic activity 
against widely diverged nematode and trematode species.
Table 3 summarizes the IC50 values for the three drugs in each species and assay tested in this study. 
Comparison of IC50s of the three drugs in a given assay and treatment duration is informative: e.g., for lethality of 
C. elegans after 48 h, the order of drug potency was sertraline > paroxetine > chlorpromazine (Fig. 1D, Table 3). 
Comparing IC50 values across species and assays is complicated by differences in the phenotypes measured and 
treatment durations. These limitations aside, several conclusions are possible. For all three assays in C. elegans, 
sertraline had the greatest anthelmintic activity (lowest IC50), with paroxetine being the next most effective in two 
of the three assays (Table 3). Inhibition of pharyngeal pumping in C. elegans during a 60 min treatment required 
much higher drug concentrations, with IC50 values ~2–10 times greater than for the lethality and motility assays 
(Fig. 2H; Table 3). It is likely that lower drug concentrations would have likewise inhibited feeding if applied for 
longer durations, but the purpose of the EPG recordings was to test whether the drugs can rapidly disrupt elec-
trical signaling, as seen with anthelmintics that target ion channels and neurotransmitter receptors16,33. All three 
drugs inhibited EPG activity within minutes (Fig. 2B,C,D), consistent with this potential mode of action. As dis-
cussed below, the relatively impermeable C. elegans cuticle may necessitate the use of higher drug concentrations, 
especially when seeking rapid responses.
The T. muris data (Fig. 3E; Table 3) illustrate the common pharmacological principle that drug effectiveness 
depends on both concentration and treatment duration: e.g., for motility impairment in T. muris adults treated 
with chlorpromazine, the IC50 value for a 1 h treatment was ~ 75 times greater than for a 24 h treatment (Table 3). 
The temporal pattern of drug effectiveness in T. muris was interesting as well. At 24 h, chlorpromazine was clearly 
the most potent drug in impairing motility, with an IC50 approximately 8–10 times smaller than the other two 
drugs (Fig. 3E, Table 3). In contrast, during the first 12 h of treatment, chlorpromazine’s potency was intermediate 
between, or similar to, sertraline and paroxetine. The finding that chlorpromazine was most effective as an anthel-
mintic against T. muris when provided at a lower concentration for a longer duration is a favorable property with 
respect to potential side effects. In A. caninum, sertraline had the lowest IC50 for both the hatching and develop-
ment assays, with paroxetine having the highest IC50 in both assays (Fig. 4D,H; Table 3). In S. mansoni, sertraline 
and paroxetine had the greatest anthelmintic activity in both somules and adults (Table 2; Fig. 6).
Comparing across species, higher drug concentrations were generally required for anthelmintic effects in 
C. elegans compared to the three parasitic helminths (Table 3). This is expected, as the C. elegans cuticle is highly 
impermeable to environmental small molecules35, likely resulting from their evolution as a free-living soil nem-
atode. The concentrations found effective in our study are comparable to other recent anthelmintic screening 
efforts in C. elegans6,36
In summary, across four divergent species of worms, sertraline consistently exhibited the highest anthelmintic 
activity with two exceptions: first, paroxetine was as effective as sertraline in impairing motility of S. mansoni 
adults after 24 h and, second, chlorpromazine was most effective in 24 h treatments of T. muris. The IC50 values of 
sertraline for 24 h treatments were remarkably similar across the different species examined in this study, varying 
only 2-fold (4.3, 7.0, 7.2, 8.4 and 8.8 μM; Table 3). Similarity in effective concentration is a favorable property 
when seeking drug candidates that can kill multiple helminth species at once.
An advantage of potentially repurposing FDA-approved drugs is their existing clinical histories with known 
dosage, side effect and tolerance profiles. An important consideration is how serum concentrations achieved 
during traditional clinical use compare with the concentrations tested in this study. The average serum levels for 
patients taking these drugs clinically are estimated at 58 nM (sertraline), 80 nM (paroxetine), and 422 nM (chlor-
promazine)37,38, considerably higher than the effective concentrations we determined in this study. For tests with 
24 to 48 h treatments, the IC50 values ranged from 0.7 to 18.2 µM (Table 3), and are approximately 10 to 300 times 
the serum levels in psychiatric patients. A caveat in these comparisons is that anthelmintic drug efficacy can differ 
in vitro and in vivo39. The ability of sertraline, paroxetine and chlorpromazine to reduce worm burdens in mam-
malian hosts, and at what dosages and administration schedules, remain to be determined. Such experiments are 
beyond the scope of the present study but are an important next step.
Ideally, clinical administration of anthelmintic drugs is limited to a single or very few doses, which is a treat-
ment protocol that differs considerably from the chronic administration of sertraline, paroxetine, or chlorprom-
azine for psychiatric purposes. It will be important to test whether treatment with a limited number of higher 
doses (alone or in combination with other anthelmintic drugs) could eliminate parasitic helminths without 
adverse side effects. Further, sertraline, paroxetine and chlorpromazine represent psychiatric classes of drugs 
that have undergone decades of extensive medicinal chemistry efforts (including but not limited to the structural 
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derivative patents referenced here40–48). Derivatives of these drugs with poor blood-brain-barrier penetrance may 
exist that could be effective anthelmintics at lower effective concentrations and without undesirable neurological 
side effects.
One of the most significant findings of this study concerns the potential mode(s) of action of sertraline, par-
oxetine and chlorpromazine in damaging and killing worms. Surprisingly, mutations in the genes responsible for 
these drugs’ anti-depressant or anti-psychotic effects in humans did not eliminate their anthelmintic activity in 
C. elegans and, in some cases, increased it (Supplementary Table S3). Furthermore, C. elegans mutants resistant 
to existing anthelmintics acting on a variety of targets (from ion channels to microtubules) retained sensitivity 
to all three drugs, suggesting that they act on different targets. Because some dopaminergic and serotonergic 
pathway mutants had moderately increased sensitivities to the drugs relative to wild-type C. elegans, the drugs 
may act via these pathways in a mechanistically distinct manner from their actions in humans. Novel pathways 
may potentially underlie their effects in helminths as well. The target or targets responsible may be evolutionarily 
conserved in nematodes and trematodes as all three drugs had anthelmintic activity vs. T. muris, A. caninum and 
S. mansoni, as well as C. elegans. Sertraline, paroxetine and chlorpromazine may, therefore, be broadly effective 
against a range of parasitic helminth species, increasing their utility in large population-based chemotherapy 
efforts. They may also represent new classes of anthelmintic drugs that could be used in combination with existing 
front-line drugs to boost effectiveness of anti-parasite treatment as well as forestall the development of parasite 
drug resistance.
Materials and Methods
C. elegans strains. Initial library screening was performed on C. elegans strain CK423 bus-8(e2698); 
bkIs423[Psnb-1::hTDP-43 + myo-2::dsRED]49. Re-testing was done in CB6055 bus-8(e2698) and in the Bristol 
N2 wild-type isolate. Strains DA2109 ser-7(tm1325); ser-1(ok345), MT9668 mod-1(ok103), AQ866 ser-4(ok512), 
MT8944 mod-5(n822), MT14984 tph-1(n4622), JT513 nrf-5(sa513), JT525 nrf-6(sa525), CB3474 ben-1(e1880), 
CB193 unc-29(e193), CB306 unc-50(e306), DA1316 avr-14(ad1305); avr-15(vu227) glc-1(pk54), NM1968 slo-
1(js379), RB2119 acr-23(ok2804), HY496 bre-1(ye4), LX704 dop-2(vs105); dop-3(vs106), OH313 ser-2(pk1357), 
CX12800 ser-3(ad1774), RB1631 ser-3(ok2007), KP4 glr-1(n2461), MT13113 tdc-1(n3419), MT9455 tbh-1(n3247), 
RM2702 dat-1(ok157), and CB1112 cat-2(e1112) were utilized for genetic analysis of anthelmintic drug mecha-
nism of action. Some strains were provided by the Caenorhabditis Genetics Center (CGC) funded by NIH Office 
of Research Infrastructure Programs (P40 OD010440), and the National Bioresource Project (Japan). WormBase 
(release WS251) was utilized for C. elegans genetic information.
Primary anthelmintic screening against C. elegans. Two hundred eighty-one compounds from the 
NIH Clinical Collection library (2013) were screened semi-quantitatively for effects on C. elegans growth and 
viability. To conduct the screen, 2 mL of nematode growth medium (NGM) were added into 12-well cell culture 
dishes. Each well was seeded with 20 µL of 10x concentrated OP-50 E.coli. After the bacterial lawn dried, bacteria 
were killed by UV irradiation to minimize metabolism of test compounds by live bacteria. Serial dilutions in 
DMSO of each drug in 20 µL total volumes were added to individual wells, to 50 µM, 25 µM, or 12.5 µM final con-
centrations. Twelve to 18 eggs of bus-8(e2698); bkIs423[Psnb-1::hTDP-43 + myo-2::dsRED] were plated and scored 
for survival, viability, and progeny production after 4 and 8 days (data summarized in Supplementary Table S1). 
The bus-8(e2692) mutation was included in the initial screening due to its greater cuticle permeability to small 
molecules50. Compounds that caused lethality or growth inhibition were re-tested against bus-8(e2698) at 50 µM 
final concentration in 2 mL NGM. Subsequent side-by-side testing of bus-8(e2692) and N2 indicated the two 
Species, Assay & Treatment Duration
IC50 (μM)
Sertraline Paroxetine Chlorpromazine
C. elegans
Lethality (48 h)a 18.2* 71.6* 133.2*
Motility (24 h)a 8.8ns 12.3ns 13.3ns
Pumping inhibition (60 min)b 52* 123ns 108ns
T. muris
Motility (1 h)c 38.4* 207.6ns 89.5ns
Motility (24 h)c 7.2ns 5.4ns 0.7*
A. caninum
Hatching (24 h)d 4.3* 6.4ns 6.1ns
Developing/hatched (24 h)d 7.0** 10.4ns 8.1ns
S. mansoni
Motility (24 h)e 8.4ns 7.5ns ND
Table 3. Summary of IC50 values for drugs, species and assays. Source of data: aFig. 1; bFig. 2; cFig. 3; dFig. 4; 
eFig. 6. Underline indicates the drug(s) with the lowest IC50 for each test. *Differs significantly from other 
values in same row; nsvalues do not differ significantly from other values labeled “ns” in same row; **differs 
significantly from paroxetine but not chlorpromazine. ND, not determined; an IC50 value could not be 
calculated.
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strains had similar sensitivities to sertraline, paroxetine, and chlorpromazine (sertraline (#047897) and paroxe-
tine (#047895) (Matrix Scientific, Colombia, SC); chlorpromazine (sc-202537, Santa Cruz Biotechnology, Santa 
Cruz, CA). Therefore, all following experiments utilized N2 (wild-type) C. elegans. For expanded dose-range 
testing, the indicated concentrations of drug were added to 2 mL NGM in 12-well dishes.
Severity score assignments for C. elegans. C. elegans were developmentally stage-matched by sodium 
hypochlorite treatment to extract embryos51. Fifty to 100 N2 or mutant C. elegans at embryo, L1, L3/4, or gravid 
adult stages were seeded onto the plates in duplicate wells at each concentration of drug tested, and scored at 
24, 48, and 72 h with additional plate surveys at 5 d to identify any delayed population growth. Scoring “points” 
were assigned at 48 h after exposure, and based on phenotypes observed throughout the total population in each 
well. Points were assigned for each phenotype observed, resulting in a final severity score for the drug dose tested 
(Table 1). Phenotypes scored were developmental delay (at least 1 developmental stage delayed compared to con-
trol, 1 point); developmental arrest (at L1 or L2 stages, 1 point); lethargy (lack of spontaneous crawling, 1 point); 
paralysis (lack of crawling even when stimulated but with head movements or nose retraction following stimu-
lation, or observable pharyngeal pumping, 1 point); toxic (>90% lethality, 2 points); or death (100% lethality, 4 
points). Movement was stimulated by gently touching affected animals with a thin platinum wire. If an animal 
failed to respond to gentle touch and had no observable pharyngeal pumping, it was scored as dead. Each drug 
concentration was tested in duplicate within an experiment, and in three independent experimental replicates. 
Adult worms were not scored for developmental delay or arrest, as they are fully developed. This decreased the 
number of points available to them, so may have led to an underrepresentation of drug toxicity in adults relative 
to younger developmental stages.
C. elegans embryo lethality scoring. Fifty to 100 C. elegans embryos were placed onto NGM plates con-
taining the indicated concentrations of drug. Individual hatched embryos were quantitatively scored at 48 h for 
survival. Paralysis or lethargy was distinguished from lethality by gently touching affected animals with a thin 
platinum wire and surveying pharyngeal pumping. If an animal failed to respond to gentle touch and had no 
visible pharyngeal pumping, it was scored as dead. Each drug concentration was tested in triplicate and results 
averaged.
WormLab C. elegans video tracking. Stage matched N2 worms were grown at 20 °C to day 1 of adult-
hood. Approximately 50 day 1 adults were transferred onto NGM plates with drugs at the indicated concentra-
tions for 18 hours. Using the video capture and analysis features of the software WormLab (Version 4.1, MBF 
Bioscience, Williston, VT, USA), 60 s video recordings with a resolution of 2592 × 1944 pixels were taken at 14 
frames/s using a Basler acA2500 digital camera. Worms with tracking times greater than 30 s were used in the 
final analysis. Straight-line speed was calculated from the positional change starting at the beginning of track to 
end of track (µm) and then divided by track recording duration (s). Each drug concentration was tested in trip-
licate and results averaged.
Anthelmintic resistance testing of C. elegans mutant strains. N2 and mutant C. elegans embryos 
were tested in parallel for resistance to sertraline, paroxetine, and chlorpromazine. Embryos were seeded onto 
12-well plates in duplicate for each drug concentration (25 μM, 50 μM, 100 μM, or 150 μM). N2 and mutant worms 
were also monitored on DMSO-only control plates to account for any developmental or movement abnormalities 
resulting from genetic mutations. Each population was observed on multiple successive days. The qualitative 
observations of rates of growth and survival were recorded as described above for severity score assignment, and 
overall differences in drug sensitivities for mutant C. elegans relative to N2 were summarized in Supplementary 
Table S3.
Electropharyngeogram recordings. Devices (‘chips’) were fabricated using soft lithographic methods52,53. 
Each chip had eight recording modules, as described previously16,33. Worms (N2 day 1 adults) were positioned 
(‘loaded’) via a network of channels into recording modules in the chip. Electrical signals were led to differential 
amplifiers and the amplified, filtered signals were digitized and acquired in Spike2 software (2500 kHz/channel; 
Cambridge Electronic Design; Cambridge, England). Before loading, worms were pre-incubated in M9 buffer54 
containing 10 mM 5HT (Sigma H7752; St. Louis, MO), henceforth termed ‘M9-5HT,’ to stimulate pharyngeal 
pumping17. M9-5HT was used for loading and then perfused via a syringe pump for a 30 min baseline EPG 
recording period. The perfused solution was then switched to M9-5HT containing a drug or solvent and EPG 
recording continued for an additional 60 min. Drug solutions in M9-5HT were prepared by serial dilution of 
stock solutions, with the highest concentration of solvent (DMSO) being 0.05%; this concentration was used for 
control recordings.
Spike2 data were down-sampled to 500 Hz/channel, exported to Igor Pro (WaveMetrics, Lake Oswego, OR, 
USA) and analyzed using a pump-recognition algorithm16. Worms randomly lodged head- or tail-first in record-
ing modules; for analysis, recordings from tail-first worms were flipped to direct the ‘E’ (muscle excitation) 
spikes upward55. The software identified the ‘E’ and ‘R’ (muscle relaxation) spike of each pump. To calculate 
pump frequency vs. time for each worm, we binned the time axis (1 s bin width), counted the pumps in each 
bin, and smoothed the result using a Gaussian weighted sliding window (S.D. = 10 s). The result was averaged 
across worms in each experimental group (ensemble average; N = number of worms in the ensemble) and plot-
ted as mean (line) ± 1 S.E.M. (shading). Pump frequency was normalized [i.e., divided by the mean pump fre-
quency during a 10 min period (t = −12 min to −2 min) near the end of the baseline period] before averaging 
across worms16. To derive IC50 values (concentration at which pump frequency was reduced by half), we calcu-
lated the mean pump frequency (non-normalized) in a time window during which the pump frequency was at 
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approximately steady state (t = 55–60 min), and averaged the result across worms in each experimental group 
(i.e., each drug concentration).
Anthelmintic testing against T. muris. Stock concentrations of sertraline, paroxetine and chlorprom-
azine were prepared by dissolving 1 mg of each drug in 10–20 µL of DMSO and then topping up with 1 mL of 
culture media (RPMI 1640 media containing 10% fetal bovine serum and antibiotic/antimycotic (AA)) to make 
1 mg/mL concentration. From this stock solution, four different concentrations (334 µg/mL, 11 µg/mL, 0.3 µg/
mL and 0.01 µg/mL of each drug were prepared for testing against the helminth nematode, Trichuris muris. These 
concentrations were converted to molarity in the Results section. Mice were orally infected with approximately 
200 T. muris eggs. After 6 wk the mice were sacrificed and adult worms harvested from the caecum. The worms 
were washed with PBS/2 × AA and resuspended in 200 µL culture medium. Parasites (3 worms/well) were trans-
ferred to sterile 96-well flat bottom microplates (Corning 3650, Life Sciences, USA) and incubated overnight at 
37 °C with 5% CO2 for background assessment and quality checks. Inter-well spaces were filled with 300 µL of 
culture medium to prevent dessication in the wells with worms and maintained in an incubator at 37 °C with 
5% CO2 until the end of experiment. T. muris were prepared in triplicate wells for each drug and concentration. 
Wells were treated with different drugs (100 µL volume added per well) of four different concentrations and the 
motility of the worms was monitored for 24 h. The effects of drugs on the motility of worms were assessed using 
published methods56. Briefly, a 5 s video recording was taken of each well of the 96 well plate using a dissection 
microscope (Olympus) fitted with a Nikon D200 camera after 1, 4, 8, 12 and 24 h. Each 5 s video capture of each 
well was processed using the software Image J (1.47 v, imagej.nih.gov/ij) and a modified macro (“wiggle index”). 
On each 96-well plate, test compounds, medium control and a 1% DMSO control were arrayed in triplicate. 
Changes in light intensity recorded during the 5 s capture were transformed into a motility index, which included 
a Gaussian image blur normalization on each digitized frame of each video. The 150-frame video was transformed 
into a projection-stack and for each pixel the standard deviation (S.D.) of light intensity was calculated for sets 
of 50 frames in a ‘rolling’ manner. The mean of the S.D. of each pixel from the S.D. of light intensity of each set 
of 50 frames was calculated to compute the final motility index for each well. Optimal thresholds were deter-
mined prior by the analysis of untreated worms (100% motility) and media only wells (0% motility). Motility 
data were obtained at 1, 4, 8, 12 and 24 h after adding drugs or control solutions to the wells. The James Cook 
University (JCU) animal ethics committee approved all experimental work involving animals (Ethic approval 
number A2271).
Anthelmintic testing against A. caninum. The effect of sertraline, paroxetine and chlorpromazine on 
hookworm larval development was assayed using center well organ culture dishes (Falcon 353037). The inner 
well of each dish was filled with 2 mL NGM agar. After solidification, 40 μL of drug at the desired concentration 
was added to each plate and allowed to dry, followed by 10 μl of an overnight E. coli OP50 culture that was added 
to the center of the agar. Hookworm eggs were isolated from feces of infected dogs by salt flotation, washed, and 
suspended at a concentration of 10 eggs/μL in BU buffer (50 mM Na2HPO4, 22 mM KH2PO4, 70 mM NaCl)57. 
Approximately 100 eggs (10 μL) were added to each plate and the exact number counted under a dissecting 
microscope. Four mL of BU buffer were added to the surrounding moat, and the dishes incubated at 27 °C for 4 
d at which time the plates were scored for worm development. Larvae that progressed beyond the L1 stage were 
considered to be developing. Any larvae that left the plate and became trapped in buffer in the outer moat were 
collected and counted. Treatments were performed in triplicate, and the experiment repeated twice. All animal 
experiments were carried out in strict accordance with the recommendations in the Guide for the Care and 
Use of Laboratory Animals of the National Institutes of Health and under a protocol approved by the George 
Washington University Medical Center Institutional Animal Care and Use Committee.
Anthelmintic testing against S. mansoni. Maintenance of the S. mansoni life cycle, preparation of 
somules and adult worms, compound storage, and co-incubation of somules or adult worms with test compounds 
were as described58–60. Somules and adults were cultured in the presence of compounds over five concentrations 
(0.625, 1.25, 2.5, 5, and 10 µM) for up to 48 h and 24 h, respectively. As reported previously, simple descriptors 
were employed to describe the observable effects of compounds on parasites (changes in shape, motility and 
density; see legend to Table 2)58,61 using an inverted microscope at 18 and 48 h post-exposure (somules) or 11 and 
24 h post-exposure (adults). To convert these observations into a partially quantitative output for comparing drug 
effects, each descriptor was awarded a score of 1 and these were summed to a maximum score of 462–64. Evidence 
of degeneracy or death was awarded the maximum score of 4. For adults specifically, damage to the tegument 
(outer surface) was also awarded a score of 4 on the understanding that surface damage is lethal to the parasite 
in vivo65. For somules, experiments utilized 40 animals per well per treatment. For adult assays, 5 adult male 
worms were tested per well per treatment. All assays were performed twice, each in duplicate.
For adult S. mansoni, we additionally employed WormAssay to measure worm motility64,66. WormAssay uses 
a commodity digital movie camera connected to an Apple Macintosh computer that operates an open source 
software application to automatically process multiple wells (in 6-, 12- or 24-well plates). The application detects 
worm-induced changes in the occupation and vacancy of pixels between frames. Worm motion was quanti-
fied using the “Consensus Voting Luminance Difference” option. Motility assays were repeated twice, each in 
duplicate.
Statistical analysis of dose-response curves. For graphical display and statistical analysis of 
dose-response data we calculated the mean (mi) and standard error of the mean (σi) of the responses at each drug 
concentration (xi) by averaging across trials. In cases where the measurement involved counting individual events 
(e.g., the number of living worms), σi was adjusted using the Wilson continuity correction67.
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To test for a significant effect of the drug on the measured response, we used a modification of the likelihood 
ratio test to determine whether the Hill equation with 4 parameters (maximum response, minimum response, 
IC50 and Hill coefficient) provided a better fit to the data than a constant, using a modification of the likelihood 
ratio test68. To compare dose-response curves between experimental treatments, Hill curves (constrained to 
approach zero at high drug concentrations) were fit to the data:
=


 +



H R b
x b (1)
i
r
i
r r0
where R0 is the response without drug, xi is the drug concentration, b = IC50 and r is the Hill coefficient. We esti-
mated the three free parameters (R0, b, r) using the Igor Pro FuncFit operation to minimize the sum of squares, 
∑ zi i
2, where σ= −z H m( )/i i i i is the deviation of the observed mean response from the Hill curve, normalized by 
dividing by σi. This weighted least squares criterion yields the maximum likelihood value of IC50 under the 
approximation that the measurement errors are drawn from independent Gaussian distributions. To test for sig-
nificant differences between IC50 values for two dose-response curves we used the likelihood ratio test69, which is 
based on the reduction in goodness-of-fit when the IC50 values are constrained to be the same for the two curves, 
which reduces the number of free parameters from 6 (three for each curve) to five. The likelihood ratio (LR) test 
statistic is:
∑ ∑− = − + −′ ′LR z z z z2 ln( ) ( ) ( )
(2)i
i i
j
j j
2 2 2 2
where the subscripts i and j denote the points on the two dose-response curves, σ′ = ′ −z H m( )/i i i i and 
σ′ = ′ −z H m( )/j j j j are the normalized deviations of the data from the constrained Hill curves ′H i and ′H j. The 
test statistic is distributed approximately as χ2 with 1 degree of freedom, from which we determined p-values.
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